| ²é¿´: 441 | »Ø¸´: 2 | |||
| ±¾Ìû²úÉú 1 ¸ö ·ÒëEPI £¬µã»÷ÕâÀï½øÐв鿴 | |||
yin198716гæ (ÕýʽдÊÖ)
|
[ÇóÖú]
µ¥¾äÇóÖú
|
||
| In summary, in recent years DLL4 has appeared as a significant regulator of tumor angiogenesis. Blockade of this ligand results in non-productive angiogenesis with an inhibitory effect on tumor growth. Nevertheless, the careful evaluation of adverse effects on physiology of normal organs in relation to therapeutic doses of DLL4 inhibitors will be critical for advancement of DLL4 blocking agents in clinical oncology. |
» ²ÂÄãϲ»¶
278Çóµ÷¼Á
ÒѾÓÐ15È˻ظ´
284Çóµ÷¼Á
ÒѾÓÐ15È˻ظ´
293µ÷¼Á
ÒѾÓÐ16È˻ظ´
273Çóµ÷¼Á
ÒѾÓÐ45È˻ظ´
22408 266Çóµ÷¼Á
ÒѾÓÐ13È˻ظ´
266Çóµ÷¼Á
ÒѾÓÐ15È˻ظ´
Ò»Ö¾Ô¸»ª¶«Àí¹¤085601²ÄÁϹ¤³Ì303·ÖÇóµ÷¼Á
ÒѾÓÐ9È˻ظ´
ÉúÎïѧ328·ÖÇóµ÷¼Á
ÒѾÓÐ4È˻ظ´
277Çóµ÷¼Á
ÒѾÓÐ6È˻ظ´
265Çóµ÷¼Á
ÒѾÓÐ21È˻ظ´

xux730
Ìú¸Ëľ³æ (ÖøÃûдÊÖ)
- ·ÒëEPI: 86
- Ó¦Öú: 1719 (½²Ê¦)
- ½ð±Ò: 10740.4
- É¢½ð: 50
- ºì»¨: 43
- Ìû×Ó: 2947
- ÔÚÏß: 336.5Сʱ
- ³æºÅ: 1374299
- ×¢²á: 2011-08-20
- רҵ: ϸ°ûÖÜÆÚÓëµ÷¿Ø
¡¾´ð°¸¡¿Ó¦Öú»ØÌû
¡ï ¡ï ¡ï ¡ï ¡ï
yin198716: ½ð±Ò+5, ·ÒëEPI+1 2013-09-23 23:44:16
yin198716: ½ð±Ò+5, ·ÒëEPI+1 2013-09-23 23:44:16
| ×ÜÖ®£¬ÔÚ×î½ü¼¸ÄêÖÐDLL4Ã÷ÏÔ³ÉΪÖ×ÁöѪ¹ÜÉú³ÉµÄÒ»¸öÏÔÖøµ÷½ÚÒò×Ó¡£×è¶Ï¸ÃÅäÌåµ¼Ö¶ÔÖ×ÁöÉú³¤¾ßÓÐÒÖÖÆÐ§¹ûµÄÎÞЧѪ¹ÜÉú³É¡£È»¶ø£¬×ÐϸÆÀ¹ÀÖÎÁƼÁÁ¿µÄDLL4ÒÖÖÆ¼Á¶ÔÕý³£Æ÷¹ÙÉúÀíÉϵIJ»Á¼Ó°Ï콫ÊÇDLL4×è¶Ï¼ÁÔÚÁÙ´²Ö×ÁöѧȡµÃ½øÕ¹µÄ¹Ø¼ü¡£ |
2Â¥2013-09-23 22:04:15
ÕŹúÓª2176
гæ (СÓÐÃûÆø)
- Ó¦Öú: 4 (Ó×¶ùÔ°)
- ½ð±Ò: 144.9
- Ìû×Ó: 57
- ÔÚÏß: 15.9Сʱ
- ³æºÅ: 2441457
- ×¢²á: 2013-04-29
- רҵ: ¹Ç¡¢¹Ø½Ú¡¢Èí×éÖ¯ËðÉËÓëÐÞ
3Â¥2013-09-23 23:00:35














»Ø¸´´ËÂ¥